ArticleAPMIS : acta pathologica, microbiologica, et immunologica Scandinavica2026
UBC9 and PI3K Expression in Colorectal Cancer: Possible Prognostic Role.
Article in APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is the second cause of cancer-related deaths worldwide. Although ubiquitin-conjugating enzyme 9 (UBC9) expression has been implicated in a variety of malignancies, its precise role in CRC remains poorly understood. Also Phosphatidylinositol 3-kinase (PI3K) signaling is known to enhance cellular proliferation in various cancers. This study aims to investigate the expression of UBC9 and PI3K in CRC, prognostic and predictive significance, and association with patients' survival. A total of 140 archival samples of CRC, 70 normal colonic tissue, and 40 metastatic lymph nodes were included. Immunohistochemistry was done for UBC9 and PI3K antibodies, and appropriate statistical analysis of results was performed. UBC9 and PI3K are highly expressed in tumor cells, where co-high expression is significantly associated with high grade, advanced stage, high lymph node ratio (LNR), lympho-vascular invasion (LVI), low tumor infiltration lymphocytes (TILs), chemo-resistance, and positive KRAS mutation, with the poorest median survival (17 months) in patients. Significant positive association was revealed between both molecules in metastatic lymph nodes. UBC9 and PI3K are related to CRC poor survival and resistance to treatment. A potential combined role of both molecules in colorectal carcinogenesis could be found.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.